Cardiovascular Diseases

Lipid Lowering Beneficial Regardless of Age

A contemporary primary prevention cohort study and a systematic review and meta-analysis showed that older people with elevated LDL cholesterol had higher absolute risk of atherosclerotic cardiovascular disease (CVD), and lipid lowering was as effective in reducing cardiovascular events as it was in younger ones. The cohort study included 13 779 individuals aged 70–100 years and 77 352 aged 20–69 years in the Danish general population from Nov 25, 2003 to Feb 17, 2015. During mean 7·7 years of follow-up, 1515 individuals had the first myocardial infarction (MI) and 3389 had atherosclerotic CVD. MI and atherosclerotic CVD increased with both higher LDL cholesterol levels and older age. The older people with higher absolute risk benefited the most from lipid lowering for primary prevention compared to younger people with higher relative risk. The meta-analysis included 244 090 patients from 29 trials (predominantly secondary prevention studies), 21 492 (8·8%) were aged at least 75 years, of whom 11 750 (54·7%) were from statin trials, 6209 (28·9%) from ezetimibe trials, and 3533 (16·4%) from PCSK9 inhibitor trials. Median follow-up ranged from 2·2 to 6·0 years. LDL cholesterol lowering significantly reduced the risk of major vascular events (n=3519) in older patients by 26% per 1 mmol/L reduction in LDL cholesterol (risk ratio 0·74), with no statistically significant difference in the risk reduction in patients younger than 75 years (0·85). Among older patients, risk ratios were not statistically different for statin (0·82) and non-statin treatment (0·67). The benefit of LDL cholesterol lowering in older patients was observed for each component of the composite, including cardiovascular death (0.85), MI (0·80), stroke (0·73), and coronary revascularization (0·80). The findings support the cumulative burden of LDL cholesterol over a person’s lifetime, and that available randomized controlled trial evidence has not indicated an upper age threshold beyond which statin therapy does not reduce risk but differ from reports from cohorts enrolled decades ago probably due to favorable changes in life expectancy. Source: https://www.thelancet.com/

hyangiu

Recent Posts

Circadian Depression Subtype Linked to More Severe Symptoms and Poorer Antidepressant Response

A circadian subtype of depression is associated with earlier disease onset, more severe clinical features,…

4 days ago

Frequent and Unintentional Daytime Napping Linked to Higher Dementia Risk

A longitudinal study of 995 U.S. older adults found that frequent and unintentional daytime napping…

5 days ago

A Common CD36 Variant of Dilated Cardiomyopathy in Individuals of African Ancestry

A multicohort genetic association study found that the ancestry-enriched CD36 Y325* variant accounted for a…

5 days ago

Exercise Prescription: A Core Component of CVD Prevention and Treatment

An American College of Cardiology scientific statement emphasizes that exercise should be prescribed as a…

5 days ago

Low-Fat Vegan Diet Improves Metabolic Health in T2D

A 16-week low-fat vegan diet was associated with significant reductions in body weight, visceral fat,…

2 weeks ago

Intensive BP Lowering Reduced Cardiovascular Risk but Increased eGFR Decline

A systematic review and meta-analysis of 27 studies involving 88,830 participants found that intensive blood…

2 weeks ago

This website uses cookies.